CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the Information Circular), which is available on SEDAR at www.sedar.com, and on the Zenith website at www.zenithepigenetics.com.
Continued here:
Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders
Related Post
- Better Choice Company Board of Directors Authorize Stock Repurchase Program - August 18th, 2021
- Comment on news - August 18th, 2021
- Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine... - August 18th, 2021
- Greenrose Acquisition Corp. Increases Full Year 2022 Financial Outlook - August 18th, 2021
- 22nd Century to Present at SNN Network Investor Conference on August 19 - August 18th, 2021
- XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium - August 18th, 2021
- Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021 - August 18th, 2021
- Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion... - August 18th, 2021
- Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and... - August 18th, 2021
- Zivo Bioscience, Inc. Issues Letter to Shareholders - August 18th, 2021
- Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency - August 18th, 2021
- Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25 - August 18th, 2021
- FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors - August 18th, 2021
- ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units - August 18th, 2021
- Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer - August 18th, 2021
- Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results - August 18th, 2021
- Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Telix and Merck to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Two New Studies to Explore Telix Assets in Breast Cancer Theranostics - August 18th, 2021
- Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region - August 18th, 2021
- Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference - July 22nd, 2021
- Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 - July 22nd, 2021
- Ladenburg Thalmann to Host R&D; Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 - July 22nd, 2021
- LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare... - July 22nd, 2021
- Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom - July 22nd, 2021
- Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory... - July 22nd, 2021
- Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing - July 22nd, 2021
- Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board - July 22nd, 2021
- Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2... - July 22nd, 2021
- Spectral Medical Inc. Announces $10 Million Offering - July 22nd, 2021
- Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021 - July 22nd, 2021
- Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug... - July 22nd, 2021
- Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update - July 22nd, 2021
- ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients - July 22nd, 2021
- Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units - July 22nd, 2021
- Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities - July 22nd, 2021
- TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock - July 22nd, 2021
- TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million - July 22nd, 2021
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results - July 22nd, 2021
- argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 - July 22nd, 2021
- Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China - July 7th, 2021
- Praxis Precision Medicines to Present at Upcoming Investor Conferences - July 7th, 2021
- Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - July 7th, 2021
- Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum - July 7th, 2021
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology - July 7th, 2021
- CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors - July 7th, 2021
- Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations - July 7th, 2021
- ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM - July 7th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021 - July 7th, 2021
- Integrity Implants and Fusion Robotics Merge to Form Accelus - July 7th, 2021
- AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET - July 7th, 2021
- FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients - July 7th, 2021
- Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional... - July 7th, 2021
- Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel... - July 7th, 2021
- NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - July 7th, 2021
- Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative... - July 7th, 2021
- Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis - July 7th, 2021
- Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - July 7th, 2021
- XBiotech Announces Dividend to Holders of Common Stock - July 7th, 2021
- Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 - July 7th, 2021
- Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference - May 28th, 2021
- Kane Biotech Announces First Quarter 2021 Financial Results - May 28th, 2021
- OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®... - May 28th, 2021
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - May 28th, 2021
- Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights - May 28th, 2021
- Ascendis Pharma A/S Reports First Quarter 2021 Financial Results - May 28th, 2021
- Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress - May 28th, 2021
- Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the... - May 28th, 2021
- Vaxcyte to Present at the Jefferies Virtual Healthcare Conference - May 28th, 2021
- AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - May 28th, 2021
- GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 - May 28th, 2021
- Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology - May 28th, 2021
- LIDDS intends to carry out a directed share issue of approximately MSEK 45 - May 28th, 2021
- Immunocore to present at upcoming investor conferences - May 28th, 2021
- MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings - May 28th, 2021
- Travere Therapeutics to Present at Upcoming Investor Conferences - May 28th, 2021
- Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq - May 28th, 2021
- Iterum Therapeutics Provides Update on NDA Review - May 28th, 2021
- Medexus Announces Amendments to its Credit Agreements - May 28th, 2021
- The performance of Olainfarm Group in Q1 2021 is convincingly resilient - May 28th, 2021